中文
In Focus
Biz in Brief
Impact
中文
SEARCH RESULTS
To create your individual collection of articles for download, tick the relevant boxes and click the download button below.
Year
ALL
2021
2022
2023
Business Unit
ALL
Corporate
Ports
Retail
Infrastructure
Energy
Telecoms
Other Business
LKSF
04.2021
Biz in Brief
HUTCHMED’s second anti-cancer drug approved in China
HUTCHMED welcomes the approval of Surufatinib for the treatment of non-pancreatic neuroendocrine tumours. A 420-strong commercial team will now bring the drug – discovered and developed completely in-house – to doctors and patients across Mainland China to help fight cancer. It will be marketed under the brand name Sulanda®. The pharmaceutical innovator has also initiated a rolling submission of its New Drug Application to the US Food and Drug Administration.
Related:
HUTCHMED
Surufatinib
R&D
Select for Download
Download
Create a PDF of your selected
stories and download
Copied to clipboard
Downloading PDF. Please wait...
Copied to clipboard
Downloading PDF. Please wait...
Subscribe for updates
I have read and accepted the
Terms & Conditions
and the
Privacy Policy
of this website.
Subscribe
Scroll